Study 24 of 30Survodutide (BI 456906) literatureNature medicine · Phase 3Top journal2026
Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Not reported in abstract.
Where it sits
this study against the rest of the survodutide (bi 456906) corpus4
Preclinical · this one
10
Observational
3
Open-label
10
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Survodutide (BI 456906) corpus
ASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2023 · n=752 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.HumanASurvodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.Contemporary clinical trials · 2026 · 18.7% body-weight reduction at 46 weeks.reviewCNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.Diabetes, obesity & metabolism · 2026 · Not reported in abstract.AnimalASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2HumanASurvodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026 · 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC, P<0.0001.HumanASurvodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026 · -12.2% mean change in body weight from baseline in the 3.6-mg group at week 76, 95% CI -13.6 to -10.8.Human